The serine/threonine Pim 1 kinase is an oncogene whose expression is deregulated in several human cancers. Overexpression of Pim 1 facilitates cell cycle progression and suppresses apoptosis. Hence pharmacologic inhibitors of Pim 1 are of therapeutic interest for cancer. ETP-45299 is a potent and selective inhibitor of Pim 1 that inhibits the phosphorylation of Bad and 4EBP1 in cells and suppresses the proliferation of several non-solid and solid human tumor cell lines. The combination of the PI3K inhibitor GDC-0941 with ETP-45299 was strongly synergistic in MV-4-11 AML cells, indicating that the combination of selective Pim kinase inhibitors and PI3K inhibitor could have clinical benefit.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canlet.2010.09.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
New antiplatelet approach: inhibiting Pim kinase to reduce constitutive surface expression of thromboxane A receptor.
J Thromb Haemost
January 2025
Systems Pharmacology and Translational Therapeutics Laboratory, at the Center for Advanced Studies and Technology (CAST), and Department of Neuroscience, Imaging and Clinical Science, "G. d'Annunzio" University Medical School, Chieti, Italy.
Constitutive surface expression of the thromboxane A2 receptor is Pim kinase-dependent.
J Thromb Haemost
January 2025
Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom; Discovery and Translational Science Department, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom. Electronic address:
Background: The thromboxane A2 receptor (TPαR) plays an important role in the amplification of platelet responses during thrombosis. Receptor activity is regulated by internalization and receptor desensitization. The mechanism by which constitutive surface expression of the TPαR is regulated is unknown.
View Article and Find Full Text PDFPIM2 inhibition promotes MCL1 dependency in plasma cells involving integrated stress response-driven NOXA expression.
Nat Commun
January 2025
Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, UMR_S1236, F-35043, Rennes, France.
Our study explores the complex dynamics of the integrated stress response (ISR) axis, highlighting PIM2 kinase's critical role and its interaction with the BCL2 protein family, uncovering key mechanisms of cell survival and tumor progression. Elevated PIM2 expression, a marker of various cancers, often correlates with disease aggressiveness. Using a model of normal and malignant plasma cells, we show that inhibiting PIM2 kinase inhibits phosphorylated BAD production and activates ISR-mediated NOXA expression.
View Article and Find Full Text PDFPIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis.
Theranostics
January 2025
Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Shandong, China.
Article Synopsis
- Endothelial-to-mesenchymal transition (EndMT) is a process where endothelial cells transform into a different cell type, contributing to the dysfunction that initiates atherosclerosis, but the exact triggers in atherosclerotic environments are not well understood.
- Research involving single-cell sequencing in mice on a high-fat diet showed that PIM1, a protein, is expressed in both endothelial cells and atherosclerotic lesions and plays a crucial role in the progression of atherosclerosis.
- Knockdown of PIM1 in endothelial cells reduced atherosclerosis and EndMT by affecting key proteins and pathways associated with cell transformation, suggesting that targeting this pathway could be a potential therapeutic approach.
RBM19 promotes the progression of prostate cancer under docetaxel treatment via SNHG21/PIM1 axis.
Cell Biol Toxicol
December 2024
Department of Urology, Jinjiang Municipal Hospital, Luoshan Section, No. 16 Jinguang Road, Luoshan Street, Jinjiang City, Quanzhou, Fujian, China.
RBM family proteins plays the critical role in the progression of numerous tumors. However, whether RBM family proteins involved in prostate cancer (PCa) progression is remain elucidated. In our study, an RNAi screen containing shRNA library targeting 54 members of the RBM family was applied to identify the critical RBM proteins involved in prostate cancer progression under docetaxel treatment, and RBM19 was selected.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!